Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml.

Shao YH, Albertsen PC, Roberts CB, Lin Y, Mehta AR, Stein MN, DiPaola RS, Lu-Yao GL.

Arch Intern Med. 2010 Jul 26;170(14):1256-61. doi: 10.1001/archinternmed.2010.221.

2.

Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.

Faisal FA, Sundi D, Pierorazio PM, Ball MW, Humphreys EB, Han M, Epstein JI, Partin AW, Carter HB, Bivalacqua TJ, Schaeffer EM, Ross AE.

BJU Int. 2014 Dec;114(6b):E120-9. doi: 10.1111/bju.12771. Epub 2014 Aug 13.

3.

Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.

D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.

Cancer. 2002 Jul 15;95(2):281-6.

4.

Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.

Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S, Mostofi FK, McLeod DG.

JAMA. 1995 Oct 25;274(16):1277-81.

PMID:
7563532
5.
7.

Who bears the greatest burden of aggressive treatment of indolent prostate cancer?

Mahal BA, Cooperberg MR, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Orio PF 3rd, Trinh QD, Nguyen PL.

Am J Med. 2015 Jun;128(6):609-16. doi: 10.1016/j.amjmed.2014.12.030. Epub 2015 Jan 30.

PMID:
25644324
8.

Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.

D'Amico AV, Renshaw AA, Sussman B, Chen MH.

JAMA. 2005 Jul 27;294(4):440-7.

PMID:
16046650
9.

Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.

Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.

Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):714-24.

PMID:
15708249
10.

Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.

Krejcarek SC, Chen MH, Renshaw AA, Loffredo M, Sussman B, D'Amico AV.

Urology. 2007 Mar;69(3):515-9.

PMID:
17382156
11.

Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.

Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, Partin AW, Pavlovich CP, Schaeffer EM.

BJU Int. 2012 Oct;110(8):1122-8. doi: 10.1111/j.1464-410X.2012.10986.x. Epub 2012 Feb 28.

12.

Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.

Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ.

Eur Urol. 2015 Feb;67(2):326-33. doi: 10.1016/j.eururo.2014.05.039. Epub 2014 Jul 2.

13.

Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.

Malik RD, Goldberg JD, Hochman T, Lepor H.

Eur Urol. 2011 Sep;60(3):548-53. doi: 10.1016/j.eururo.2011.05.036. Epub 2011 May 26.

PMID:
21652145
14.

The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.

Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL.

BJU Int. 2012 Jul;110(1):36-42. doi: 10.1111/j.1464-410X.2011.10681.x. Epub 2011 Nov 15.

15.

Maximum tumor diameter and the risk of prostate-specific antigen recurrence after radical prostatectomy.

Rose BS, Chen MH, Zhang D, Hirsch MS, Richie JP, Chang SL, Hegde JV, Loffredo MJ, D'Amico AV.

Clin Genitourin Cancer. 2014 Oct;12(5):e173-9. doi: 10.1016/j.clgc.2014.03.008. Epub 2014 Mar 28.

PMID:
24787967
16.

Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.

Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR.

J Urol. 2003 Jan;169(1):157-63.

PMID:
12478126
17.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

18.

Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance.

Kim J, Ebertowski J, Janiga M, Arzola J, Gillespie G, Fountain M, Soderdahl D, Canby-Hagino E, Elsamanoudi S, Gurski J, Davis JW, Parker PA, Boyd DD.

BJU Int. 2013 May;111(6):934-40. doi: 10.1111/j.1464-410X.2012.11768.x. Epub 2013 Jan 25. Retraction in: BJU Int. 2014 Mar;113(3):509.

19.

Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?

Keyser D, Kupelian PA, Zippe CD, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):723-9.

PMID:
9240638
20.

Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.

Carlsson S, Maschino A, Schröder F, Bangma C, Steyerberg EW, van der Kwast T, van Leenders G, Vickers A, Lilja H, Roobol MJ.

Eur Urol. 2013 Nov;64(5):693-9. doi: 10.1016/j.eururo.2013.04.040. Epub 2013 May 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk